Conference Announcement | You are cordially invited to attend the 2026 Huangpu Cell and Gene Innovation Conference!
Release Date:
2026-06-23 11:41
At present, China’s cell and gene therapy sector is entering a new phase of law-based, standardized development. On May 1, 2026, State Council Order No. 818, the Regulations on the Clinical Research and Clinical Translation of New Biomedical Technologies, officially came into effect, providing a clear policy framework and end-to-end regulatory pathways for technology translation. As the core hub for biopharmaceuticals in the Guangdong–Hong Kong–Macao Greater Bay Area, Guangzhou’s Huangpu District has attracted more than 4,800 biopharmaceutical enterprises, amassed a dense network of top-tier hospitals and national-level research platforms, and established the first one-stop service center for new biomedical technologies in South China, thereby fostering a comprehensive ecosystem that spans the entire value chain—from basic research and pilot-scale translation to clinical application and industrial-scale production.
Against this backdrop, the “2026 Huangpu Cell and Gene Innovation Conference” is scheduled to be held on June 26–27, 2026, at the South China New Materials Innovation Park in Huangpu District, Guangzhou. The event will align closely with national strategies and local policies, establishing a specialized forum framework of “1+1+6” and bringing together government, industry, academia, research institutions, end-users, and investors. Its aim is to bridge the “last mile” of technology translation, fostering the standardized implementation and high‑quality commercialization of cell and gene therapies in areas such as rare diseases and critical illnesses.
Hycells has established an integrated business system comprising “sample services—specialized products—technology service platform,” thereby forming a structure centered on… Primary immune cells , with stem cells and hepatocytes as the core of its strategic business portfolio. Centered on immune cells and Stem cell culture Throughout the entire process, the company has developed a one-stop comprehensive solution that encompasses six core modules: compliant seed cells, HiMag. TM Sorting kit, HiXpan ® Serum-free culture Kit, HiXpan ® Platelet lysate, Cell Feeder底透 cell culture flasks, and HiXpan ® Serum-free cell cryopreservation solution. This closed-loop cell culture system integrates a comprehensive product portfolio, providing efficient, stable, and compliant end-to-end technical support for both research and industrialization projects, thereby continuously empowering the independent innovation and development of China’s biopharmaceutical industry.
We cordially invite industry peers to attend the exhibition, engage in in-depth discussions, and jointly explore avenues for growth.
Hycells Bio Booth Number: A39
Meeting time:
June 26–27, 2026
Meeting Location:
No. 31, Kefeng Road, Huangpu District, Guangzhou, South China New Materials Innovation Park
Organizational Structure:
Guiding Unit: Guangzhou Municipal Science and Technology Bureau, Guangzhou Huangpu District Health Commission, Guangzhou Huangpu District Administration for Market Regulation, Guangzhou Huangpu District Science and Technology Bureau
Organizer: Guangdong Precision Medicine Application Society, Guangzhou Development Zone Biopharmaceutical and Health Industry Promotion Association
Organizing Unit: Guangzhou South China New Materials Innovation Park Co., Ltd., the Precision Immunotherapy Branch of the Guangdong Society for Precision Medicine Applications, the Biotherapy Branch of the Guangdong Society for Precision Medicine Applications, and the Science and Technology Finance Working Committee of the Guangdong Society for Precision Medicine Applications.
Conference Size:
Total size: 1,000+ people
Among them: medical institutions (20%); cell and gene therapy companies and upstream/downstream enterprises (60%); universities and research institutes (10%); investment firms (5%); government, industry associations, media, and others (5%).
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board